Cytek Biosciences earnings were -$11.3M for the trailing 12 months ending Mar 31, 2025, with 48.3% growth year over year. The latest CTKB earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$11.4M, down 218.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CTKB reported annual earnings of -$6.0M, with -50.4% growth.
CTKB past earnings growth
How has CTKB's earnings growth performed historically?
What were Cytek Biosciences's earnings last quarter?
On CTKB's earnings call on Invalid Date, Cytek Biosciences (NASDAQ: CTKB) reported Q1 2025 earnings per share (EPS) of -$0.09, up 80% year over year. Total CTKB earnings for the quarter were -$11.40 million. In the same quarter last year, Cytek Biosciences's earnings per share (EPS) was -$0.05.
As of the last Cytek Biosciences earnings report, Cytek Biosciences is currently losing money. Cytek Biosciences's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$11.25 million, a 2.24% decrease year over year.
What was CTKB's earnings growth in the past year?
As of Cytek Biosciences's earnings date in Invalid Date, Cytek Biosciences's earnings has grown 48.32% year over year. This is 0.61 percentage points lower than the US Medical Devices industry earnings growth rate of 48.93%. CTKB earnings in the past year totalled -$11.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.